Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07JWO
|
|||
| Former ID |
DNCL002312
|
|||
| Drug Name |
IL-21
|
|||
| Synonyms |
BMS-982470
Click to Show/Hide
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1], [2] | |
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-21 (IL21) | Target Info | Modulator | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Inflammatory bowel disease (IBD) | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| WikiPathways | Allograft Rejection | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4987). | |||
| REF 2 | ClinicalTrials.gov (NCT01152788) Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma. U.S. National Institutes of Health. | |||
| REF 3 | National Cancer Institute Drug Dictionary (drug id 409696). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.